`Tel: 571-272-7822
`
`Paper 10
`Entered: July 2, 2020
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`MYLAN LABORATORIES LTD.
`Petitioner,
`
`v.
`
`JANSSEN PHARMACEUTICA NV,
`Patent Owner.
`
`
`IPR2020-00440
`Patent 9,439,906
`
`
`
`
`
`
`
`
`
`Before JOHN G. NEW, KRISTINA M. KALAN, and ROBERT A.
`POLLOCK, Administrative Patent Judges.
`PER CURIAM
`
`
`
`ORDER
`Granting Petitioner’s and Patent Owner’s Requests for Authorization for
`Additional Briefing
`37 C.F.R. § 42.5
`
`
`
`
`
`
`
`
`
`
`
`IPR2020-00440
`Patent 9,439,906
`
`
`In response to an email request by Petitioner Mylan Laboratories Ltd.
`(“Mylan”), a telephonic conference was held on June 30, 2019 at 1:00 p.m.
`EDT. Present were counsel for both Mylan and Patent Owner Janssen
`Pharmaceuticals N.V. (“Janssen”). A preliminary transcript of the call was
`filed as Exhibit 1048.
`Mylan requests authorization to file a Reply Brief in Response to
`Janssen’s Preliminary Response (Paper 8). Specifically, Mylan seeks
`authorization to respond to Janssen’s arguments with respect to 35 U.S.C.
`§§ 314(a) and 325(d) in view of the factors set forth in the Board’s recent
`decision in Apple Inc. v. Fintiv, Inc., IPR2020-00019 (March 20, 2020)
`(precedential). Mylan also seeks authorization to respond to Janssen’s
`arguments with respect to whether Janssen’s patent-in-suit can claim the
`priority benefit of Janssen’s U.S. Provisional Application No. 61/014,918
`(the “’918 application”). Mylan requests ten pages to brief these issues, to
`be submitted one week subsequent to an order authorizing the briefing.
`Janssen does not oppose Mylan’s request with respect to the
`§§ 314(a)/325(d) issue, but opposes additional briefing with respect to the
`priority issue. However, if Mylan’s request is granted, Janssen seeks
`authorization to also file a Sur-Reply in response to Mylan’s submitted
`Reply Brief.
`
`Having considered the arguments presented by both sides in the
`conference, we determine that further briefing would be useful for our
`determination whether to institute trial. Accordingly we authorize Mylan’s
`request to file a Reply with respect to both issues and we likewise authorize
`Janssen’s request to file a Sur-Reply to address both issues. The Reply and
`Sur-Reply briefings on both issues are limited to a combined ten-page limit
`2
`
`
`
`
`IPR2020-00440
`Patent 9,439,906
`
`for each, and subject to the requirements of 37 C.F.R. § 42.6(a). Mylan’s
`Reply shall be submitted no later than one week following the issuance of
`this order, and Janssen’s Sur-Reply shall be filed no later than one week
`subsequent to the filing of Mylan’s Reply.
`
`
`ORDER
`
`It is therefore,
`ORDERED that Mylan’s request to file a Reply Brief on both issues is
`authorized, said Reply Brief not to exceed ten pages, and to be filed no later
`than July 10, 2020, and
`FURTHER ORDERED that Janssen is authorized to file a Sur-Reply
`in response to Mylan’s Reply, said Sur-Reply not to exceed ten pages, and to
`be filed no later than July 17, 2020.
`
`
`
`
`
`
`3
`
`
`
`
`IPR2020-00440
`Patent 9,439,906
`
`PETITIONER:
`
`Jitendra Malik, Ph.D.
`Guylaine Haché, Ph.D.
`Alissa M. Pacchioli
`Lance Soderstrom
`KATTEN MUCHIN ROSENMAN LLP
`jitty.malik@katten.com
`alissa.pacchioli@katten.com
`lance.soderstrom@katten.com
`
`PATENT OWNER:
`
`Barbara L. Mullin
`Andrew D. Cohen
`Joong Youn (Jay) Cho
`PATTERSON BELKNAP WEBB & TYLER LLP
`bmullin@pbwt.com
`acohen@pbwt.com
`jcho@pbwt.com
`
`Ruben H. Munoz
`AKIN GUMP STRAUSS HAUER & FELD LLP
`rmunoz@akingump.com
`
`
`
`4
`
`
`